Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog
J.-P. Clement MD

J.-P. Clement MD

Executive Pharmacovigilance Consulting

Connect with J.-P. Clement MD on LinkedIn
Website:

About the author:

Dr. Clement is an Executive Pharmacovigilance Consultant for the pharmaceutical industry. He has worked over the last 26 years in Drug Safety and Pharmacovigilance in multiple capacities, mostly with global PV responsibilities at the VP level. He has worked for companies such as Janssen, Merck KgA, Abbott, Sanofi, Onyx and Cubist His consulting practice focuses on helping Pharmaceutical Companies to design and implement highly efficient and compliant PV structures and processes, with high strategic output. Dr. Clement graduated in Family Medicine from Pierre and Marie Curie Medical University, Paris, France, and worked in clinical practice for 8 years before joining the pharmaceutical industry. He also studied Pharmacology at Pierre & Marie Curie Paris 6, Lariboisiere Paris 5 and Claude Bernard Lyon Universities, France.


Posts by J.-P. Clement MD

How to Establish a Solid PV Training Curriculum?

Posted on April 5th, 2017 in Pharmacovigilance

There are many elements to consider when you develop a training curriculum for your PV team. A training curriculum defines which roles (rather than individuals) in a group should be trained on which processes. Here are some elements to consider if you want to maximize your training efforts in order to be efficient, compliant and inspection-ready. Continue reading “How to Establish a Solid PV Training Curriculum?” »

Building PV SOPs: Where to start?

Posted on March 17th, 2017 in Pharmacovigilance

Having a set of operating standards defined through Quality Documents (QDs) is the only route to compliance and performance. QDs are defined as documents such as Policies, SOPs, Work Instructions (WINs), Manuals, Charters and Memo to File. Continue reading “Building PV SOPs: Where to start?” »

PV Audit by Quality: Friends or Foes?

Posted on March 9th, 2017 in Pharmacovigilance

One of the major ways to measure the health of a Pharmacovigilance (PV) organization is to organize regular audits by experienced Quality Assurance (QA) auditors. During such audits, how open should PV be with the auditors Continue reading “PV Audit by Quality: Friends or Foes?” »

The Art of CAPA Writing

Posted on February 13th, 2017 in Pharmacovigilance

Corrective and Preventive Actions (CAPAs) are a fundamental element of correcting deviation compliance in a regulated and quality Pharmacovigilance environment. Continue reading “The Art of CAPA Writing” »

  1. 1
  2. 2
  3. 3
  4. 4